Recommended Topic Related To:

Caverject Powder

"For men with low testosterone, taking testosterone along with Viagra may not help their erections more than if they only took Viagra, a new study shows.

“There were lots of reasons to think that it would work," Boston University rese"...

Caverject Powder

INDICATIONS

CAVERJECT is indicated for the treatment of erectile dysfunction due to neurogenic, vasculogenic, psychogenic, or mixed etiology.

Intracavernosal CAVERJECT may be a useful adjunct to other diagnostic tests in the diagnosis of erect ile dysfunct ion.

DOSAGE AND ADMINISTRATION

The dose of CAVERJECT should be individualized for each patient by careful titration under supervision by the physician. In clinical studies, patients were treated with CAVERJECT in doses ranging from 0.2 to 140 micrograms; however, since 99% of patients received doses of 60 micrograms or less, doses of greater than 60 micrograms are not recommended. In general, the lowest possible effective dose should always be employed. In clinical studies, over 80% of patients experienced an erection sufficient for sexual intercourse after intracavernosal injection of CAVERJECT. A 1/2-inch, 27- to 30- gauge needle is generally recommended.

Initial Titration in Physician's Office

Erectile Dysfunction of Vasculogenic, Psychogenic, or Mixed Etiology. Dosage titration should be initiated at 2.5 micrograms of alprostadil. If there is a partial response, the dose may be increased by 2.5 micrograms to a dose of 5 micrograms and then in increments of 5 to 10 micrograms, depending upon erectile response, until the dose that produces an erection suitable for intercourse and not exceeding a duration of 1 hour is reached. If there is no response to the initial 2.5-microgram dose, the second dose may be increased to 7.5 micrograms, followed by increments of 5 to 10 micrograms. The patient must stay in the physician's office until complete detumescence occurs. If there is no response, then the next higher dose may be given within 1 hour. If there is a response, then there should be at least a 1-day interval before the next dose is given.

Erectile Dysfunction of Pure Neurogenic Etiology (Spinal Cord Injury). Dosage titration should be initiated at 1.25 micrograms of alprostadil. The dose may be increased by 1.25 micrograms to a dose of 2.5 micrograms, followed by an increment of 2.5 micrograms to a dose of 5 micrograms, and then in 5-microgram increments until the dose that produces an erection suitable for intercourse and not exceeding a duration of 1 hour is reached. The patient must stay in the physician's office until complete detumescence occurs. If there is no response, then the next higher dose may be given within 1 hour. If there is a response, then there should be at least a 1-day interval before the next dose is given.

The majority of patients (56%) in one clinical study involving 579 patients were titrated to doses of greater than 5 micrograms but less than or equal to 20 micrograms. The mean dose at the end of the titration phase was 17.8 micrograms of alprostadil.

Maintenance Therapy

The first injections of CAVERJECT must be done at the physician's office by medically trained personnel. Self-injection therapy by the patient can be started only after the patient is properly instructed and well trained in the self-injection technique. The physician should make a careful assessment of the patient's skills and competence with this procedure. The intracavernosal injection must be done under sterile conditions. The site of injection is usually along the dorso-lateral aspect of the proximal third of the penis. Visible veins should be avoided. The side of the penis that is injected and the site of injection must be alternated; the injection site must be cleansed with an alcohol swab.

The dose of CAVERJECT that is selected for self-injection treatment should provide the patient with an erection that is satisfactory for sexual intercourse and that is maintained for no longer than 1 hour. If the duration of erection is longer than 1 hour, the dose of CAVERJECT should be reduced. Selfinjection therapy for use at home should be initiated at the dose that was determined in the physician's office; however, dose adjustment, if required (up to 57% of patients in one clinical study), should be made only after consultation with the physician. The dose should be adjusted in accordance with the titration guidelines described above. The effectiveness of CAVERJECT for long-term use of up to 6 months has been documented in an uncontrolled, self-injection study. The mean dose of CAVERJECT at the end of 6 months was 20.7 micrograms in this study.

Careful and cont inuous follow-up of the patient while in the self-injection program must be exercised. This is especially true for the initial self-injections, since adjustments in the dose of CAVERJECT may be needed. The recommended frequency of injection is no more than 3 times weekly, with at least 24 hours between each dose. The reconstituted vial of CAVERJECT is intended for single use only and should be discarded after use. The user should be instructed in the proper disposal of the syringe, needle, and vial.

While on self-injection treatment, it is recommended that the patient visit the prescribing physician's office every 3 months. At that time, the efficacy and safety of the therapy should be assessed, and the dose of CAVERJECT should be adjusted, if needed.

CAVERJECT as an Adjunct to the Diagnosis of Erectile Dysfunction

In the simplest diagnostic test for erectile dysfunction (pharmacologic testing), patients are monitored for the occurrence of an erection after an intracavernosal injection of CAVERJECT. Extensions of this testing are the use of CAVERJECT as an adjunct to laboratory investigations, such as duplex or Doppler imaging, 133Xenon washout tests, radioisotope penogram, and penile arteriography, to allow visualization and assessment of penile vasculature. For any of these tests, a single dose of CAVERJECT that induces an erection with firm rigidity should be used.

General Procedure for Solution Preparation

CAVERJECT is packaged in a 5-milliliter glass vial. Bacteriostatic water for injection or sterile water, both preserved with benzyl alcohol 0.945% w/v, must be used as the diluent for reconstitution. After reconst itut ion with 1 millili ter of diluent, the volume of the resulting solution is 1.13 milliliters. One millili ter of this solut ion will contain 5.4, 10.5, 20.5 or 41.1 micrograms of alprostadil depending on vial strength, 172 milligrams of lactose, 47 micrograms of sodium citrate and 8.4 milligrams of benzyl alcohol. The deliverable amount of alprostadil is 5, 10, 20 or 40 micrograms per milliliter because approximately 0.4 microgram for the 5 microgram strength, 0.5 microgram for the 10 and 20 microgram strengths and 1.1 microgram for the 40 microgram strength is lost due to adsorption to the vial and syringe. After reconstitution, the solution of CAVERJECT should be used within 24 hours when stored at or below 25°C (77°F) and not refrigerated or frozen. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever the solution and container permit.

HOW SUPPLIED

CAVERJECT is a dry lyophilized powder and is supplied in vials containing 6.15, 11.9, 23.2 or 46.4 micrograms of alprostadil for intracavernosal administration. Store the 5, 10 and 20 microgram strengths at or below 25°C (77°F).

Store the 40 microgram strength at 2° to 8°C (36° to 46°F) until dispensed. After dispensing, the CAVERJECT 40 microgram strength may be stored at or below 25°C (77°F) for 3 months or until expiration date, whichever occurs first.

When reconstituted and used as directed, the deliverable amount of alprostadil is 5, 10, 20 or 40 micrograms, respectively. The reconstituted solution should be used within 24 hours when stored at or below 25°C (77°F) and not refrigerated or frozen. Only the accompanying diluent or bacteriostatic water for injection with benzyl alcohol should be used when reconstituting CAVERJECT. CAVERJECT is available in the following packages:

6-10 microgram vials............................NDC 0009-3778-05
6-20 microgram vials............................NDC 0009-3701-05
6-40 microgram vials............................NDC 0009-7686-04

Other available packages:

6-5 microgram vials with diluent syringes............................NDC 0009-7212-03
6-10 microgram vials with diluent syringes............................NDC 0009-3778-08
6-20 microgram vials with diluent syringes............................NDC 0009-3701-01

Pharmacia & Upjohn Company, A subsidiary of Pharmacia Corporation Kalamazoo, MI 49001, USA., Revised October 2002. FDA rev date: 9/2/2003

Last reviewed on RxList: 3/3/2008
This monograph has been modified to include the generic and brand name in many instances.

A A A

Caverject - User Reviews

Caverject User Reviews

Now you can gain knowledge and insight about a drug treatment with Patient Discussions.

Here is a collection of user reviews for the medication Caverject sorted by most helpful. Patient Discussions FAQs

Report Problems to the Food and Drug Administration

 

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.



Sex & Relationships

Get tips to boost your love life.